Article · Wikipedia archive · Last revised Jul 18, 2026

CT-4201

CT-4201 is a serotonergic psychedelic which is under development for the treatment of major depressive disorder. It is a prodrug of the tryptamine psychedelic psilocin that is said to have improved pharmacokinetic properties compared to psilocybin, the primary active constituent of psilocybin-containing mushrooms. CT-4201 is being developed by CaaMTech. As of November 2024, it is in the preclinical research stage of development.

Last revised
Jul 18, 2026
Read time
≈ 1 min
Length
179 w
Citations
13
Source
Wikipedia ↗
CT-4201
Clinical data
Other namesCT4201
Drug classNon-selective serotonin receptor agonist; Serotonin 5-HT2A receptor agonist; Serotonergic psychedelic; Hallucinogen
ATC code
  • None

CT-4201 is a serotonergic psychedelic which is under development for the treatment of major depressive disorder.123 It is a prodrug of the tryptamine psychedelic psilocin that is said to have improved pharmacokinetic properties compared to psilocybin, the primary active constituent of psilocybin-containing mushrooms.12345 CT-4201 is being developed by CaaMTech.123 As of November 2024, it is in the preclinical research stage of development.12

See also

See also

References

References

  1. "Delving into the Latest Updates on CT-4201 with Synapse". Synapse. 8 May 2025. Retrieved 1 August 2025.
  2. Haichin M. "Psychedelics Drug Development Tracker". Psychedelic Alpha. Retrieved 1 August 2025.
  3. "FDA Endorses CaaMTech's Psilocin Drug Development For Depression Treatment". Sahm. 14 November 2024. Retrieved 1 August 2025.
  4. "CaaMTech receives FDA endorsement for psilocin depression drug development". SPEEDA Edge. 14 November 2024. Retrieved 1 August 2025.
  5. "CaaMTech Receives Regulatory Validation for Functional Unblinding Strategy in Psilocin Prodrug Trial". MedPath. 15 November 2024. Retrieved 1 August 2025.